Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Paradoxical Findings in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors: Suboptimal Disease Control Perceived As Satisfactory

Anna Gaya, Luis Fernando Fernández Fuertes, Mónica Ballesteros Andrés, Silvia De La Iglesia Íñigo, Rafael Andrés Del Orbe Barreto, Fernando Fernández Fuertes, Ana Pilar Gonzalez, Isidro Jarque, Esperanza Lavilla, Ramiro Nuñez Vasquez, Eduardo José Salido, Maria Vahí, Carlos Vallejo

Blood (2023) 142 (Supplement 1): 5645.

https://doi.org/10.1182/blood-2023-185939

Published: 2023

Journal Articles

Improved Clinical Outcomes and Replacement FVIII Consumption in Patients with Hemophilia a after Prophylaxis Adjustment Using a FVIII Pharmacokinetics Estimation Based on Bayesian Models

Maria Eva Mingot-Castellano, PhD, Rafael Parra, PhD, Ramiro Nuñez, MD, Marta Martorell, Ana Isabel Heiniger Mazo, MD

Blood (2016) 128 (22): 3780.

https://doi.org/10.1182/blood.V128.22.3780.3780

Published: 2016

Journal Articles

Assessment of Hematologic and Visceral Parameters in Patients with Type 1 Gaucher Disease in Spain: An Epidemiological Study Using the Therapeutic Goals MAP (Monitor, Action and Progress) Tool ®

Pilar Giraldo, Jordi Perez, Ramiro Núñez, Rafael Fernandez de la Puebla, Elisa Luño, Salvador Saura, Juan Carlos Bureo, Javier de la Serna, Sylvia Plaza, Víctor Navas

Blood (2014) 124 (21): 4963.

https://doi.org/10.1182/blood.V124.21.4963.4963

Published: 2014

Journal Articles

Factor XIII Deficiency As Underlying Cause Of Unexplained Bleeding

Marta Ruiz Mercado, Silvia Verdesoto Cozzarelli, Cristina Calderón-Cabrera, Ramiro Núñez Vázquez, Reyes Jiménez Bárcenas, Rosario Pérez Garrido, Jose Antonio Pérez-Simón, Francisco Javier Rodríguez Martorell

Blood (2013) 122 (21): 4776.

https://doi.org/10.1182/blood.V122.21.4776.4776

Published: 2013

Journal Articles

Efficacy and Safety of Fludarabine/Cyclophosphamide (FC) as Front-Line Treatment of CLL. Final Results of a Phase II Clinical Trial in a Single Center.

Ana Marin-Niebla, MD, Eduardo Rios-Herranz, MD, Juan M. Rodriguez, PhD, Ramiro Nunez, MD, Ascension Herrera, MD, Ricardo Parody, MD, Ildefonso Espigado, PhD.

Blood (2004) 104 (11): 4826.

https://doi.org/10.1182/blood.V104.11.4826.4826

Published: 2004

NARROW

Paradoxical Findings in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors: Suboptimal Disease Control Perceived As Satisfactory

Improved Clinical Outcomes and Replacement FVIII Consumption in Patients with Hemophilia a after Prophylaxis Adjustment Using a FVIII Pharmacokinetics Estimation Based on Bayesian Models

Assessment of Hematologic and Visceral Parameters in Patients with Type 1 Gaucher Disease in Spain: An Epidemiological Study Using the Therapeutic Goals MAP (Monitor, Action and Progress) Tool ®

Factor XIII Deficiency As Underlying Cause Of Unexplained Bleeding

Efficacy and Safety of Fludarabine/Cyclophosphamide (FC) as Front-Line Treatment of CLL. Final Results of a Phase II Clinical Trial in a Single Center.

Email alerts

ASH Publications

American Society of Hematology

Paradoxical Findings in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors: Suboptimal Disease Control Perceived As Satisfactory

Improved Clinical Outcomes and Replacement FVIII Consumption in Patients with Hemophilia a after Prophylaxis Adjustment Using a FVIII Pharmacokinetics Estimation Based on Bayesian Models

Assessment of Hematologic and Visceral Parameters in Patients with Type 1 Gaucher Disease in Spain: An Epidemiological Study Using the Therapeutic Goals MAP (Monitor, Action and Progress) Tool ®

Factor XIII Deficiency As Underlying Cause Of Unexplained Bleeding

Efficacy and Safety of Fludarabine/Cyclophosphamide (FC) as Front-Line Treatment of CLL. Final Results of a Phase II Clinical Trial in a Single Center.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only